The invention relates to a nicotine oral delivery product containing a powder enclosed in a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said powder comprising at least a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and b) a chewing gum composition and a method of producing said nicotine oral delivery product.

The invention relates to stable pharmaceutical formulation useful for the oral administration comprising a peptide or protein drug and a permeation enhancer. In particular, the invention relates to stabilized pharmaceutical formulations comprising GLP-1 receptor agonist such as Semaglutide and a permeation enhancer and its process for preparation.

Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

The disclosure provides compositions adapted for oral use and, in particular, multi-compartment oral pouched products including such compositions. Some aspects of the disclosure relate to oral pouched products including a composition adapted for oral use within a porous pouch. In particular, the porous pouch may include two or more compartments, each compartment having a content of the composition contained therein. The composition within each compartment can be different such that the composition within each compartment provides a different functional or sensory experience, such as through use of a different flavoring agent, a different active ingredient, or both a different flavoring agent and a different active ingredient.

The invention provides polymeric particles comprising a matrix of a biocompatible polymer and polyethylene imine, said matrix having incorporated therein an anionic or hydrophobic sonosensitiser and, optionally, an immunomodulatory agent and/or an imaging agent. Such particles find use in methods of sonodynamic therapy, in particular in methods of combined sonodynamic therapy and immunotherapy, for example in the treatment of cancer, metastasis or micrometastasis derived from cancer. The invention is particularly suitable for the treatment of deep-sited, hard to treat tumours such as pancreatic cancer.

The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

An oral product in the form of an edible film is provided herein. The edible film can include a binder in an amount of at least about 30 percent by weight; a plasticizer in an amount of at least about 5 percent by weight; and an active agent, wherein the edible film is orally dissolvable. The edible film can also be used as a component of another oral product, e.g., a fleece-based pouched product. The edible film can form a coating on a portion of an interior or exterior surface of a fleece-based pouched product.

A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing a powder composition having an amount of one or more cannabinoids and a water-insoluble composition including cellulose and/or fibers in the form of particles in an amount of 30 to 80% by weight of the powder composition. The powder composition further includes a water-soluble composition comprising one or more sugar alcohols and the pouch includes a water-permeable membrane. A pouch designed for administration of an active ingredient in the oral cavity is also disclosed.

An orally administered hydrogel composition includes: an alginate polymer that forms a gel in aqueous solution, in the presence of a cation; an aqueous solution, in a sufficient amount; an agent for dissolving said alginate polymer in the aqueous solution; a gelation retarder; and a floating agent to form gas bubbles in the hydrogel composition the hydrogel formed by using the hydrogel composition being dissolved by using an orally administered dissolving agent. The invention applies in particular to the production of gastric implants.

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.